World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
116
Citations
119911
World Ranking
4245
National Ranking
20

Michael Gnant publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael Gnant sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 798 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael Gnant D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Gnant sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 116 D-Index — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael Gnant is affiliated with the Medical University of Vienna in Austria and has contributed extensively to research in oncology, particularly focusing on breast cancer. Their work spans multiple aspects of cancer biology, treatment, and clinical management, with a significant number of publications in esteemed journals.

Their main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology, with subfields concentrated in Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics, and Surgery. This multidisciplinary engagement reflects a comprehensive approach to cancer research and treatment development.

Key research topics addressed by Michael Gnant include:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Global Cancer Incidence and Screening
  • Breast Lesions and Carcinomas
  • BRCA gene mutations in cancer

Michael Gnant has coauthored numerous papers with other researchers, frequently collaborating with:

  • Christian F. Singer
  • Marija Balić
  • Florian Fitzal
  • Richard Greil
  • Dominik Hlauschek

Their publication record includes articles in prominent scientific journals. Frequent publication venues include:

  • Cancer Research
  • Journal of Clinical Oncology
  • The Breast
  • Annals of Oncology
  • Clinical Cancer Research

Recent papers authored or coauthored by Michael Gnant illustrate a focus on breast cancer therapies and clinical guidelines. Notable publications include:

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021, published in 2021 in Annals of Oncology
  • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, published in 2023 in Annals of Oncology
  • Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, published in 2022 in Annals of Oncology
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, published in 2021 in The Lancet Oncology
  • Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial, published in 2021 in Journal of Clinical Oncology

Best Publications

  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

    A.G. Olsson;J McMurray;G Thorgeirsson;C Spaulding

  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

    R Turner;C Fox;Matthews;H McElroy

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

    UK Prospective Diabetes;RR Holman;SE Manley;R Turner

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Prevention of neural tube defects: Results of the Medical Research Council vitamin study

    N Wald;J Sneddon;J Densem;C Frost

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    José Baselga;Mario Campone;Martine Piccart;Howard A. Burris

  • Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group.

    J. F. Sneddon;J Densem;N Wald;C Frost

  • Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    A. S. Coates;E. P. Winer;A. Goldhirsch;R. D. Gelber

  • Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

    Michael Gnant;Brigitte Mlineritsch;Walter Schippinger;Gero Luschin-Ebengreuth

  • Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

    Raimund Jakesz;Walter Jonat;Michael Gnant;Martina Mittlboeck

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

    Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

    Martin Filipits;Margaretha Rudas;Raimund Jakesz;Peter Dubsky

  • Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

    Michael Gnant;Brigitte Mlineritsch;Herbert Stoeger;Gero Luschin-Ebengreuth

  • Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial

    Thomas M. Suter;Marion Procter;Dirk J. van Veldhuisen;Michael Muscholl

  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

    Terje R Pedersen

Frequent Co-Authors

Raimund Jakesz
Raimund Jakesz Medical University of Vienna
Richard Greil
Richard Greil Paracelsus Medical University
Christian F. Singer
Christian F. Singer Medical University of Vienna
Christoph C. Zielinski
Christoph C. Zielinski Medical University of Vienna
Kathleen I. Pritchard
Kathleen I. Pritchard University of Toronto
Jonas Bergh
Jonas Bergh Karolinska Institute
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Martine Piccart
Martine Piccart Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees and career pathways can be a practical choice for those interested in medicine, especially with the flexibility of online study. There is a growing demand for roles in pharmacy, health informatics, medical billing, and nursing—all of which offer accredited online programs.

For students considering the pharmaceutical field, comparing online pharmacy school cost is key. Affordable options exist, but tuition rates and prerequisites vary widely. Similarly, health data specialists are in high demand, and earning a degree in health informatics can open doors to careers in hospital data management and healthcare analytics.

If you are interested in administrative roles, enrolling in online medical billing and coding courses can be a quick way to start working in healthcare. Those seeking advanced patient care roles should investigate the cheapest np programs online. These programs offer a pathway to a high-impact healthcare career while managing costs.

Best Scientists Citing Michael Gnant

Trending Scientists

Recently Published Articles